Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Western Union Co — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Western Union Co trades at $6.05 (market cap $1.90B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 4× Western Union Co's market cap, and Western Union Co pays a 15.41% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Western Union Co for 96 Days on average.
| SYRE | WU | |
|---|---|---|
Market Cap | $7.52B | $1.90B |
Volume | 1,441,031 | 6,506,793 |
Sector | Health | Financials |
52-Week High | $108.92 | $10.28 |
52-Week Low | $22.18 | $5.90 |
Typical Hold Time | 0 Days | 96 Days |
Enterprise Value | $6.52B | $1.81B |
Dividend Yield | — | 15.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Western Union (WU) trades at $6.05, down 0.98% on the day and near its 52-week low of $6.00. The stock shows bearish technical signals with recent earnings misses in Q1 and Q2 2026. Fundamentally, WU maintains strong profitability with a 9.79% net margin and attractive valuation metrics including a P/E of 4.92. The company's $200 million cost-cutting initiative and Intermex acquisition aim to drive future growth despite revenue declines from $4.5B in 2022 to $4.05B in 2025.
WU presents a value opportunity with deep undervaluation but faces execution risks. The stock trades below analyst consensus target of $6.71, offering 11% upside potential. However, declining revenue trends, integration challenges from the Intermex acquisition, and competitive pressures in money transfer services create headwinds. Investor sentiment remains cautious with only 12% buy ratings from analysts, reflecting concerns about the company's digital transition and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
